TNX-201
Phase 2Small molecule
TNX-201 is one of 14 small molecule programs targeting Tension-type headache. It is currently in Phase 2.
1
Indications
2
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Tension-Type Headache
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Reglan
IIstituto Clinico Humanitas
Approved
Advil
KKenvue Brands
Approved
Toradol
JJavelin Pharmaceuticals
Approved
Tylenol
KKenvue Brands
Approved
Alka-Seltzer
AAbbott
Approved
Acetylsalicylic Acid
BayerApproved
Namenda
AbbViePhase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Novel Ibuprofen
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TNX-201. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTonix Pharmaceuticals, Inc.